StockData
Fuller H B Co logo

Fuller H B Co (FUL) stock analysis

FULNYSEAdhesives & SealantsFiscal year ends November 28
Financials through Q3 FY2026, quarter ended Aug 29, 2026Last filing: 10-Q on Sep 24, 2026Score 18/3051% below fair value
$50.65−0.13 (-0.26%)

Close on Nov 11, 2026Market cap $2.73BP/E 14.1Yield 1.83%

StockData Score

Prices as of Nov 11, 2026How the score works

Value6Growth3Performance3Health2Dividend4

Solid18 of 30 checks passed

Fuller H B passes 18 of the 30 checks behind our score; 2 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
6/6
Growth
3/6
Past performance
3/6
Financial health
2/6
Dividend
4/6

What stands out

  • Margin of safety over 20%

    The price is 51.1% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $50.65 is below our fair value estimate of $103.58.

  • Earnings grew over 5 years

    Net income grew 4.2% a year on average over the last five fiscal years.

  • Earnings growth accelerating

    Net income grew 72.2% over the last twelve months, against a 5-year average of 4.2% a year.

What to watch

  • Return on equity under 15%

    Return on equity was 9.6% over the last twelve months and averaged 9.2% over five years; we look for 15% on both.

  • High debt

    Debt is 94.8% of shareholders' equity, above the 40% we consider low.

  • Revenue growing under 10% a year

    Revenue grew -2.5% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -5.5% a year over the last three fiscal years.

Valuation6/6
  • P/E below its 5-year median

    Fuller H B's P/E of 14.1 is below its own 5-year median of 23.9.

  • P/E below the industry

    Fuller H B's P/E of 14.1 is below the Chemicals and Allied Products median of 25.2.

  • EV/EBITDA below its 5-year median

    Fuller H B's EV/EBITDA of 8.0 is below its 5-year median of 16.4.

  • P/B below the industry

    Fuller H B's price-to-book of 1.26 is below the Chemicals and Allied Products median of 2.24.

  • Trading below fair value

    The share price of $50.65 is below our fair value estimate of $103.58.

  • Margin of safety over 20%

    The price is 51.1% below fair value, more than the 20% cushion we look for.

Growth3/6
  • Revenue growing under 10% a year

    Revenue grew -2.5% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -5.5% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 72.2% over the last twelve months, against a 5-year average of 4.2% a year.

  • Growing slower than the industry

    Revenue grew 1.5% over the last twelve months; the Chemicals and Allied Products median is 11.0%.

  • Guidance raised

    Fuller H B raised its fiscal 2026 Cash flow from operations outlook on Sep 24, 2026.

  • Gross margin improving

    Gross margin was 32.3% over the last twelve months, against 30.4% a year earlier.

Past performance3/6
  • Return on equity under 15%

    Return on equity was 9.6% over the last twelve months and averaged 9.2% over five years; we look for 15% on both.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity above the industry

    Fuller H B's return on equity of 9.6% is above the Chemicals and Allied Products median of 7.4%.

  • Earnings grew over 5 years

    Net income grew 4.2% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 5.6% over the last twelve months, against a 5-year average of 4.4%.

  • Net margin below the industry

    Fuller H B's net margin of 5.6% is below the Chemicals and Allied Products median of 5.6%.

Financial health2/6
  • High debt

    Debt is 94.8% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 127% five years ago to 94.8%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 14.1% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 1.82 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 1.86; above 3 is the safe zone and below 1.8 the distress zone.

Dividend4/6
  • Pays a dividend

    Fuller H B paid dividends worth 1.9% of the share price over the last twelve months.

  • Yield below Treasuries

    The 1.9% yield is below the 4.4% on a 1-year Treasury.

  • Yield below the top quarter

    The top quarter of US dividend payers yield 3.8% or more; Fuller H B yields 1.9%.

  • Dividend not cut

    The dividend per share has not fallen by more than 10% in any of the last 10 fiscal years.

  • Covered by earnings

    Dividends take 26.2% of net income.

  • Covered by free cash flow

    Dividends take 51.8% of free cash flow.

Scores of similar companies

Our estimate per share

$103.58

The share price is 51% below this estimate.

20%+ below
Near fair value
20%+ above
$50.65Price$103.58Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E24.6×23.9×25.2×$88.2340%
EV/EBITDA17.6×16.4×18.8×$154.7435%
P/B2.2×2.2×2.2×$88.9610%
Earnings power9.7% cost of equity––$34.8615%
Fair value$103.58100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 23.9
  • Chemicals and Allied Products median 25.2

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$34.26M
Value traded per 1% price move
$25.83M

Downside

Medium risk

Typical loss in a bad month
20.2%
Volatility (annualized)
34%
Sharpe ratio, 1 year
-0.49
Beta to the S&P 500 (5Y)
0.96

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

31.1%+4.0 pts over 5 years

Operating margin

–

Net margin

4.4%−0.1 pts over 5 years

See a number that looks wrong?